Working… Menu

Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00221988
Recruitment Status : Unknown
Verified September 2005 by University Hospitals Cleveland Medical Center.
Recruitment status was:  Recruiting
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
Michael Schoenberg, Ignacio Pita, Kyra Dawson
Information provided by:
University Hospitals Cleveland Medical Center

Brief Summary:
Epilepsy is a common disorder with an incidence of about 6 per 1000. The incidence progressively increases above age 50. By age 75, the incidence is two to three fold compared with any age group. Unfortunately, older individuals are especially at risk to incur significant side effects to anti-epileptic drugs. A newer anti-epileptic drug may markedly improve seizure management in older individuals as it is removed by the kidneys and not the liver and does not interact with other medications. We expect it to be tolerated well in terms of effects on memory, thinking,balance, and walking. The current study assesses the side effects of levetiracetam in healthy volunteers aged 65 to 80. Use of healthy volunteers eliminates the effects of seizures on the outcome.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Levetiracetam (Keppra) Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Cross-Over Study of the Cognitive and Mood Effects of KEPPRA (Levetiracetam) Tablets in Healthy Older Adults.
Study Start Date : March 2004
Study Completion Date : September 2005

Primary Outcome Measures :
  1. 1.Objective Neuropsyhological testing
  2. 2.Subjective Behavioral Measures
  3. 3.Balance Measures

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years to 80 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Study Population Inclusion Criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply. A subject must:

  1. Provide a copy of their medical records from a primary care physician for the past year to assist in establishing the patient's current health status. The study physician will review PCP medical records to assure participants meet the study inclusion/exclusion criteria.
  2. Be a healthy adult age 65 to 80 years old. Healthy subjects are defined as individuals who are free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological and psychiatric disease as determined by history and physical examination.
  3. Be, in the investigator's opinion, compliant, able to follow the investigator's instructions and visit the clinic on schedule, cooperative and reliable.
  4. Subjects must score within -1.0 standard deviations of the mean performance of healthy individuals on the neuropsychological tests at screen (week -2). Subjects must have a reading equivalency of 8th grade. Participants must also have a MMSE score of 28. (Bravo & Herbert, 1997; Crum et al., 1993). Finally, participants must score a 45 or better on the Berg Balance Test at screening (week -2) to be included in the study.
  5. Sign an informed consent.
  6. For participants living alone, provide the name and number of at least one friend or family member that study personnel may contact in the unlikely event that study personnel are unable to contact the patient by phone past 48 hours of a scheduled phone contact time which was not planned.

Exclusion Criteria:

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply. A subject must not:

  1. Have a history of any type of epilepsy.
  2. Be taking any concomitant medications that are or any concomitant medications that may alter cognitive function or mood.
  3. Have a current or past history of drug or alcohol abuse or dependence. Have a positive urine toxicology test at screen.
  4. Have a history and clinical finding of a progressive encephalopathy including CNS tumors of all types.
  5. Have a serious illness in the past month that may confound the interpretation of study results.
  6. Be on anticoagulation with warfarin.
  7. Have experienced a prior adverse reaction or hypersensitivity to either study medication or to related compounds.
  8. Be currently participating in another clinical study in which the subject will be exposed to an investigational or a non-investigational drug or device.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00221988

Layout table for location contacts
Contact: Mary Ann Werz, M.D., Ph,D. 216-844-3717
Contact: Mike R Schoenberg, Ph.D. 216-844-5820

Layout table for location information
United States, Ohio
University Hospitals of Cleveland Recruiting
Cleveland, Ohio, United States, 44106
Contact: Mary Ann Werz, M.D., Ph.D.    216-844-3100   
Contact: Mary Ann Werz, M.D.    216-844-3717   
Principal Investigator: Mary Ann Werz, M.D., Ph.D.         
Principal Investigator: Mike R sCHOENBERG, Ph.D.         
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Michael Schoenberg, Ignacio Pita, Kyra Dawson
Layout table for investigator information
Principal Investigator: Mary Ann Werz, M.D., Ph.D. University Hospitals Cleveland Medical Center
Principal Investigator: Mike R Schoenberg, Ph.D. University Hospitals Cleveland Medical Center
Layout table for additonal information Identifier: NCT00221988    
Other Study ID Numbers: UCB MRS001
UHC 06-04-52
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: September 22, 2005
Last Verified: September 2005
Keywords provided by University Hospitals Cleveland Medical Center:
Health Outcome
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Nootropic Agents